Mentioned 14× · first seen 28-apr-2026 · last seen 27-sep-2026

Accelerated/blast phase MPN pre-transplant bridging

Current understanding

Accelerated (AP) and blast phase (BP) MPNs are a high-unmet-need pre-transplant setting where optimal bridging is undefined; options include multi-agent AML-like chemotherapy, hypomethylating agents (decitabine), or proceeding directly to transplant. An ongoing phase II trial is evaluating decitabine combined with a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) as a novel bridging strategy versus chemotherapy or no pre-transplant therapy.

Evidence log

2026-09-19 — Clinicopathologic Characteristics of SomaticMutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review.: Same systematic review confirms TP53 mutations are enriched in AP/BP MPN with high VAF but shows multi-hit vs single-hit status no longer stratifies OS at this phase — suggesting TP53 allelic configuration is not a useful bridging-strategy discriminator in AP/BP, where universally poor outcomes push toward the earliest feasible transplant regardless of TP53 hit count. (novelty: 3)
2026-07-18 — Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.: Mayo NGS/AML-subtype series reports post-MPN AML treated with 7+3 induction has only 27% CR/CRi and 0% 5-year transplant-censored survival — distinctly worse than post-MDS AML — arguing against standard intensive induction as a bridging strategy and reinforcing the need for HMA/JAK-inhibitor-based combinations (and rapid transplant) in AP/BP MPN. (novelty: 3)
2026-06-30 — A systematic review of 47 published cases of extramedullary hematopoiesis in myelofibrosis: clinical patterns, treatment responses, and prognostic implications.: Systematic review of 47 atypical EMH cases in MF reports frequent ruxolitinib and locoregional-therapy responses, positioning JAK-inhibitor-based bridging (and targeted radiation) as a plausible strategy to control extramedullary disease before transplant in this advanced-disease subgroup. (novelty: 3)
2026-07-01 — Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms: Phase I trial extends the pacritinib + HMA bridging paradigm by adding venetoclax (BCL-2 inhibitor), testing a novel triple combination (pacritinib + venetoclax + azacitidine) for AP/BP MPN — a multi-pathway strategy aimed at deeper cytoreduction to enable transplant in this high-unmet-need population with no standard of care. (novelty: 4)
2026-06-01 — Cytokine receptor and JAK/STAT pathway mutations in acute myeloid leukemia: Prevalence and clinical impact.: Observational analysis of 971 AML patients confirms blast-phase MPN has the worst prognosis among Cy-JAK/STAT-mutated AML (13% response rate), reinforcing the rationale for novel bridging strategies and early transplant referral in AP/BP MPN; notably, de novo AML with JAK2/CALR/MPL mutations does comparatively better, with poor outcomes driven by co-occurring high-risk features rather than the driver mutation itself. (novelty: 3)
Foundation — FDA Awards $18 Million in Grants for Advancing Treatment of Rare Diseases: FDA awarded $750K to Johns Hopkins for CD8-reduced T cells targeting MDS/AML arising from MPN progression, signaling a cellular-immunotherapy direction relevant to the AP/BP MPN population beyond chemotherapy/HMA bridging. (novelty: 3)
2026-05-15 — Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse: Tangentially related: decitabine appears here inside the conditioning regimen (with FLAG-Ida + TBI) rather than as pre-transplant bridging, raising sequencing questions about HMA exposure timing relative to transplant in high-risk myeloid disease including CMML. (novelty: 3)
2026-03-04 — Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms: Phase II trial of pacritinib added to azacitidine or decitabine as bridging therapy aims to increase the proportion of AP/BP-MPN patients reaching alloHCT, extending JAK-inhibitor + HMA combinations beyond ruxolitinib/fedratinib to pacritinib (cytopenia-tolerant JAK2/IRAK1 inhibitor). (novelty: 3)
2026-03-30 — Inqovi Maintenance Therapy in Myeloid Neoplasms: cross-connection with post-transplant-maintenance-hma: HMAs used for AP/BP MPN bridging pre-transplant may also have a role as post-transplant maintenance, raising sequencing and resistance questions. (novelty: 3)
2026-04-03 — A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation: Tangentially related: a Phase 1 trial of CIML NK cells + IL-2 is evaluating salvage immunotherapy for post-HCT relapse in AML/MDS/MPN, relevant to AP/BP MPN patients given their elevated post-transplant relapse risk. (novelty: 4)
2026-03-16 — Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms: cross-connection with pretransplant-ruxolitinib: Ruxolitinib bridging is being formally extended from chronic-phase MF into AP/BP MPN via combination with decitabine in an ongoing phase II trial. (novelty: 3)